Waldenström Macroglobulinemia Treatment Moves Away From Chemotherapy
What we have been doing more frequently over the past 10 years is focusing on nonchemotherapeutic approaches to treat patients with Waldenström macroglobulinemia
The past decade has seen significant progress in research and treatment options for Waldenström macroglobulinemia, with a shift away from traditional chemotherapy toward targeted and non-chemotherapeutic therapies.
Shifting to targeted, less toxic therapies improves survival and reduces treatment-related morbidity.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Waldenström Macroglobulinemia Clinical Trials
- Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?